1YI Stock Overview
A clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Purple Biotech Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.46 |
| 52 Week High | ₪1.41 |
| 52 Week Low | ₪0.43 |
| Beta | 0.39 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -90.00% |
| 5 Year Change | n/a |
| Change since IPO | -97.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1YI | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.9% | -2.6% |
| 1Y | n/a | -15.2% | 7.1% |
Return vs Industry: Insufficient data to determine how 1YI performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 1YI performed against the German Market.
Price Volatility
| 1YI volatility | |
|---|---|
| 1YI Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 1YI has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 1YI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 20 | Gil Efron | purple-biotech.com |
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy.
Purple Biotech Ltd Fundamentals Summary
| 1YI fundamental statistics | |
|---|---|
| Market cap | €10.85m |
| Earnings (TTM) | -€17.19m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs 1YI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1YI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$196.00k |
| Gross Profit | -US$196.00k |
| Other Expenses | US$18.57m |
| Earnings | -US$18.76m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.061 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 1YI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/12 01:51 |
| End of Day Share Price | 2024/05/15 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Purple Biotech Ltd is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Emily Bodnar | H.C. Wainwright & Co. |
| Raghuram Selvaraju | Rodman & Renshaw, LLC |